Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

Brought to you by

Actavis/Watson divest four generics to Novartis' Sandoz

Executive Summary

Watson Pharmaceuticals Inc. and Actavis Group are divesting four products to Novartis AG’s Sandoz (generics) in order to comply with the FTC’s requirements to complete Watson's $5.6bn acquisition of Actavis.
Deal Industry
  • Pharmaceuticals
    • Generic Drugs
Deal Status
  • Final
Deal Type
  • Alliance
    • Product Purchase

Related Companies